ALIMTA is a type of chemotherapy called an anti-folate.
As a chemotherapy, it is believed to help to kill or slow the growth of cancer cells. However, it may also have an impact on healthy cells, which can cause serious side effects.
ALIMTA can be used in combination with an immunotherapy called KEYTRUDA and platinum chemotherapy.
ALIMTA + KEYTRUDA® (pembrolizumab) and platinum chemotherapy (carboplatin or cisplatin) all treat cancer in different ways.
ALIMTA and platinum chemotherapy are chemotherapies that attack cancer, while KEYTRUDA is an immunotherapy that works with your immune system to fight it.
ALIMTA and platinum are chemotherapies used to treat advanced nonsquamous nonsquamous non-small cell lung cancer (NSCLC) cells that are dividing quickly in your body. By adding KEYTRUDA to this combination, your body’s own immune system is also used to detect and fight cancer cells. Using these 2 types of treatments together may help to attack your cancer in a more effective way than ALIMTA and platinum alone.
ALIMTA + KEYTRUDA and platinum chemotherapy have the potential to attack healthy cells too, which can become serious and could lead to death.
ALIMTA with carboplatin or cisplatin is the first chemotherapy approved for use with KEYTRUDA.
In a clinical study, ALIMTA was given with either carboplatin or cisplatin and a type of immunotherapy called KEYTRUDA.* As a first treatment option for all Programmed death-ligand 1 (PD-L1) levels, this chemotherapy and immunotherapy combination was the first to be approved by the FDA for people who have nonsquamous NSCLC that has spread.
ALIMTA is not appropriate for people who have a different type of NSCLC called squamous cell.